Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation

被引:49
作者
Cummins, N. W. [1 ,2 ]
Deziel, P. J. [2 ]
Abraham, R. S. [3 ]
Razonable, R. R. [1 ,2 ]
机构
[1] Mayo Clin, Coll Med, Dept Internal Med, Div Infect Dis, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, William J von Liebig Transplant Ctr, Rochester, MN 55905 USA
[3] Mayo Clin, Coll Med, Dept Lab Med & Pathol, Cellular & Mol Immunol Lab, Rochester, MN 55905 USA
关键词
cytomegalovirus; immunity; outcome; kidney transplantation; T cells; CD8+; late onset; LIVER-TRANSPLANTATION; ANTIVIRAL PROPHYLAXIS; RECIPIENTS; OUTCOMES; RISK; INFECTION; MORTALITY;
D O I
10.1111/j.1399-3062.2008.00344.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
N.W. Cummins, P.J. Deziel, R.S. Abraham, R.R. Razonable. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation.Transpl Infect Dis 2009: 11: 20-27. All rights reserved Cytomegalovirus (CMV) is a major cause of morbidity and mortality among transplant recipients. The routine use of anti-CMV prophylaxis has modified the epidemiology of post-transplant CMV infection by delaying the onset of clinical disease. While the majority of delayed-onset CMV disease still occurs during the first year after transplant, reports of late-onset CMV disease presenting many years after transplantation are increasing. Here, we describe 2 CMV-seropositive transplant recipients who presented with late-onset CMV disease at 8 and 11 years after transplantation. To determine whether CMV disease occurring at a very late period after transplantation is related to immune competence, we assessed global and CMV-specific cellular immunity by evaluating the activation capability of CD8+ T cells to a mitogenic stimulus and by quantitative and functional analysis (as assessed by intracellular cytokine production and degranulation) of CMV-specific CD8+ T cells. In both patients, we demonstrated the absence or marked deficiency of CMV-specific T-cell immunity despite CMV seropositivity, and in one patient, a partial defect in the immune response to phorbol myristate acetate and ionomycin suggesting impaired global immune competence. Hence, our data suggest that late-onset CMV disease occurring many years after transplantation remains related to defects in the immune competence of patients. Measurement of CMV-specific cellular immune competence may therefore provide an additional tool to screen for patients at high risk of developing late-onset CMV disease. The clinical utility of this assay, however, will need to be evaluated in larger prospective studies.
引用
收藏
页码:20 / 27
页数:8
相关论文
共 16 条
  • [1] Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation
    Arthurs, Supha K.
    Eid, Albert J.
    Pedersen, Rachel A.
    Kremers, Walter K.
    Cosio, Fernando G.
    Patel, Robin
    Razonable, Raymund R.
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 46 (06) : 840 - 846
  • [2] Delayed-onset primary cytomegalovirus disease after liver transplantation
    Arthurs, Supha K.
    Eid, Albert J.
    Pedersen, Rachel A.
    Dierichising, Ross A.
    Kremers, Walter K.
    Patel, Robin
    Razonable, Raymund R.
    [J]. LIVER TRANSPLANTATION, 2007, 13 (12) : 1703 - 1709
  • [3] Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity
    Boeckh, M
    Leisenring, W
    Riddell, SR
    Bowden, RA
    Huang, ML
    Myerson, D
    Stevens-Ayers, T
    Flowers, MED
    Cunningham, T
    Corey, L
    [J]. BLOOD, 2003, 101 (02) : 407 - 414
  • [4] Immunologic predictors of late cytomegalovirus disease after solid organ transplantation - An elusive goal?
    Boeckh, Michael
    Riddell, Stanley R.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (05): : 615 - 617
  • [5] Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes
    Eid, Albert J.
    Arthurs, Supha K.
    Deziel, Paul J.
    Wilhelm, Mark P.
    Razonable, Raymund R.
    [J]. CLINICAL TRANSPLANTATION, 2008, 22 (02) : 162 - 170
  • [6] Cytomegalovirus disease in solid organ transplant recipients: advances lead to new challenges and opportunities
    Eid, Albert J.
    Razonable, Raymund R.
    [J]. CURRENT OPINION IN ORGAN TRANSPLANTATION, 2007, 12 (06) : 610 - 617
  • [7] Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients
    Humar, A
    Mazzulli, T
    Moussa, G
    Razonable, RR
    Paya, CV
    Pescovitz, MD
    Covington, E
    Alecock, E
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (05) : 1065 - 1070
  • [8] Primary cytomegalovirus disease after five years of antiviral prophylaxis
    Kijpittayarit, S
    Deziel, P
    Eid, AJ
    Razonable, RR
    [J]. TRANSPLANTATION, 2006, 81 (01) : 137 - 138
  • [9] Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients
    Kijpittayarit-Arthurs, Supha
    Eid, Albert J.
    Kremers, Walter K.
    Pedersen, Rachel A.
    Dierkhising, Ross A.
    Patel, Robin
    Razonable, Raymund R.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (10) : 1019 - 1024
  • [10] Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: Late-onset disease and indirect consequences
    Legendre, Christophe
    Pascual, Manuel
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 46 (05) : 732 - 740